Patterns of Care in Patterns of Care in Medical OncologyMedical Oncology

Adjuvant Chemotherapy

In general, when using chemotherapy in the In general, when using chemotherapy in the adjuvant setting for patients with adjuvant setting for patients with smaller, smaller,

node-negativenode-negative, HER2-negative tumors,, HER2-negative tumors, what tends to be the most common what tends to be the most common

regimen you use?regimen you use?

2006 2007

Clinical investigators (CI)

TC 16% 39%

AC 60% 41%*

AC/taxane regimens 7% 6%

CMF 9% 4%

Other 8% 10%

* 14% of CIs use dose-dense AC

In general, when using chemotherapy In general, when using chemotherapy in the adjuvant setting for patients with in the adjuvant setting for patients with smaller, smaller, node-negativenode-negative, HER2-negative , HER2-negative

tumors,tumors, what tends to be the most common what tends to be the most common regimen you use?regimen you use?

2006 2007

Practicing oncologists (PO)

TC 3% 21%

AC 65% 52%*

AC/taxane regimens 19% 20%

CMF 4% 5%

Other 9% 2%

* 9% of POs use dose-dense AC

In general, when using chemotherapy in In general, when using chemotherapy in the adjuvant setting for patients with the adjuvant setting for patients with

node-positivenode-positive, HER2-negative tumors,, HER2-negative tumors, what tends to be the most common what tends to be the most common chemotherapy regimen you use? chemotherapy regimen you use?

2006 2007

Clinical investigators (CI)

Dose-dense AC paclitaxel q2wk 71% 63%

AC paclitaxel q3wk 0% 0%

TAC 16% 20%

AC docetaxel q3wk 4% 0%

Other 9% 17%

In general, when using chemotherapy in In general, when using chemotherapy in the adjuvant setting for patients with the adjuvant setting for patients with

node-positivenode-positive, HER2-negative tumors,, HER2-negative tumors, what tends to be the most common what tends to be the most common chemotherapy regimen you use? chemotherapy regimen you use?

2006 2007

Practicing oncologists (PO)

Dose-dense AC paclitaxel q2wk 51% 54%

AC paclitaxel q3wk 20% 7%

TAC 13% 12%

AC docetaxel q3wk 10% 7%

Other 6% 20%

What percent of your patients with What percent of your patients with node-negativenode-negative breast cancer who breast cancer who

receive adjuvant chemotherapy receive receive adjuvant chemotherapy receive regimens that include taxanes?regimens that include taxanes?

2005 2006 2007

Clinical investigators (CI)

Mean 32% 40% 58%

Practicing oncologists (PO)

Mean 28% 38% 44%

* All participants other than 2 POs had heard about the study.

Where have you received information about Where have you received information about TC as reported by the US Oncology Group? TC as reported by the US Oncology Group?

(May have more than one response)*(May have more than one response)*

Attending the 2005 San Antonio Breast Cancer Symposium

84% 18%

Reading the Journal of Clinical Oncology

73% 61%

Listening to audio interviews or roundtable discussions in the Breast Cancer Update series

27% 39%

Other live or enduring continuing education programs

20% 21%

Reading another journal or print piece 6% 25%

Clinical investigators Practicing oncologists

Have you utilized the adjuvant TC regimen?Have you utilized the adjuvant TC regimen?

2006 2007

Clinical investigators (CI)

Percent answering yes 55% 76%

Practicing oncologists (PO)

Percent answering yes 23% 55%

How would you compare TC How would you compare TC (docetaxel/cyclophosphamide) to AC?(docetaxel/cyclophosphamide) to AC?

Antitumor efficacyAntitumor efficacy

2006 2007

Clinical investigators (CI)

TC is significantly more efficacious 11% 16%

TC is somewhat more efficacious 66% 62%

Both are similar in efficacy 23% 22%

AC is somewhat more efficacious 0% 0%

AC is significantly more efficacious 0% 0%

2007 CI n = 50

How would you compare TC How would you compare TC (docetaxel/cyclophosphamide) to AC?(docetaxel/cyclophosphamide) to AC?

Antitumor efficacyAntitumor efficacy

2006 2007

Practicing oncologists (PO)

TC is significantly more efficacious 11% 3%

TC is somewhat more efficacious 42% 27%

Both are similar in efficacy 43% 64%

AC is somewhat more efficacious 4% 5%

AC is significantly more efficacious 0% 1%

2007 PO n = 135

2006 2007

Clinical investigators (CI)

TC has significantly better safety and tolerability

5% 8%

TC has somewhat better safety and tolerability

40% 51%

Both are similar in safety and tolerability

36% 29%

AC has somewhat better safety and tolerability

19% 10%

AC has significantly better safety and tolerability

0% 2%

How would you compare TC How would you compare TC (docetaxel/cyclophosphamide) to AC?(docetaxel/cyclophosphamide) to AC?

Safety and tolerabilitySafety and tolerability

How would you compare TC How would you compare TC (docetaxel/cyclophosphamide) to AC?(docetaxel/cyclophosphamide) to AC?

Safety and tolerabilitySafety and tolerability

2006 2007

Practicing oncologists (PO)

TC has significantly better safety and tolerability

7% 11%

TC has somewhat better safety and tolerability

49% 48%

Both are similar in safety and tolerability

36% 32%

AC has somewhat better safety and tolerability

7% 8%

AC has significantly better safety and tolerability

1% 1%

2007 PO n = 140

Have you ordered the OncoHave you ordered the Oncotypetype DX™ assay? DX™ assay?

2005 2006 2007

Clinical investigators (CI)

Percent answering yes 80% 96% 98%

Practicing oncologists (PO)

Percent answering yes 34% 48% 75%

If yes, for how many patients?If yes, for how many patients?2005 2006 2007

Clinical investigators (CI)

Mean 8 15 27

Practicing oncologists (PO)

Mean 5 10 14

When the OncoWhen the Oncotypetype DX assay is DX assay is requested for your patients, who requested for your patients, who

generally initiates the order?generally initiates the order?

Medical oncologist 92% 90%

Surgeon 4% 4%

Other/do not use 4% 6%

Clinical investigators Practicing oncologists

If you had breast cancer and were If you had breast cancer and were diagnosed with a 2-cm, ER-positive, diagnosed with a 2-cm, ER-positive,

node-negative tumor with an Onconode-negative tumor with an Oncotypetype DX DX recurrence score in the intermediate range, recurrence score in the intermediate range, how comfortable would you be participating how comfortable would you be participating in the TAILORx study, in which you would in the TAILORx study, in which you would

be randomly assigned to hormonal therapy be randomly assigned to hormonal therapy with or without chemotherapy?with or without chemotherapy?

Very comfortable 48% 21%

Somewhat comfortable 24% 30%

Neutral 6% 18%

Somewhat uncomfortable 12% 19%

Very uncomfortable 10% 12%

Clinical investigators Practicing oncologists

Are you aware of the MammaPrintAre you aware of the MammaPrint®® assay? assay?

Percent answering yes 100% 49%

Clinical investigators Practicing oncologists